GlassScriptPhysician profile
Warren L Macy
NPI 1295718310
$3,487.77
in general payments reported to CMS, 2019-2025
34 companies · $561 in 2025
The $561 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $58.21 · 2021: $121 · 2022: $568 · 2023: $769 · 2024: $823 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,152.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $759.58 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $478.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $424.35 | 2022-2025 | |
| Novo Nordisk INC | $312.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corium, LLC | $198.37 | 2022-2025 | Azstarys |
| Exact Sciences Corporation | $137.68 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.06 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.83 | 2019-2025 | Jardiance |
| Amgen INC. | $113.05 | 2019-2022 | |
| Glaxosmithkline, LLC. | $102.27 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $79.80 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $62.77 | 2023-2024 | Rexulti |
| Abbott Laboratories | $56.10 | 2022-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $45.56 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $42.00 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40.30 | 2019 | |
| Almatica Pharma LLC | $39.89 | 2023 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $38.71 | 2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $38.48 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $27.08 | 2024 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $25.06 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.54 | 2023 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $20.24 | 2022 | |
| Lundbeck LLC | $19.68 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $18.93 | 2023 | |
| Exelixis INC. | $16.97 | 2022 | |
| Axsome Therapeutics, INC. | $16.93 | 2023 | Auvelity |
| Viatris Specialty LLC | $16.90 | 2025 | Yupelri |
| Eisai INC. | $16.70 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.60 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.01 | 2019 | |
| Allergan, INC. | $13.53 | 2019 | |
| Amarin Pharma, INC. | $12.53 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Macy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.